In fact, demand has been so high that it's been surpassing supply, forcing Lilly and rival Novo Nordisk to invest in ...

Starter doses of the weight-loss drug Zepbound are ... Patients “should not use a compounded drug if an approved drug is available,” the agency has said. Eli Lilly has also raised concerns ...

"When FDA-approved medicines are ... surging demand for Lilly and Danish rival Novo Nordisk's (NOVOb.CO), opens new tab weight-loss drugs, which can cost more than $1,000 for a month's supply ...

(Reuters) -Eli Lilly has sent cease-and-desist letters to U.S. healthcare providers in recent days to stop the promotion of the compounded versions of its drugs for weight loss and diabetes ...

Drug giant Eli Lilly says ... "It's a weight loss drug, but it's probably more than that," he said, citing heart disease and diabetes, for which the drugs are already approved, and potentially ...

Aug 20 (Reuters) - Eli Lilly's (LLY.N), opens new tab weight-loss drug ... showed the drug helped cut weight significantly in obese patients, helping it to secure U.S. regulatory approval.

Eli Lilly’s weight-loss drug, Zepbound ... The data at that time showed the drug helped cut weight significantly in obese patients, helping it to secure US regulatory approval. It was unclear if the ...

(Reuters) -Eli Lilly's weight-loss drug ... at that time showed the drug helped cut weight significantly in obese patients, helping it to secure U.S. regulatory approval. It was unclear if ...